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ABSTRACT
Bone turnover markers (BTMs) are product of bone cell activity and are generally divided in bone formation 
and bone resorption markers. The purpose of this review was to structure the available information on the use 
of BTMs in studies on small ruminants, especially for monitoring their variations related to diet, exercise, 
gestation and metabolic lactation state, circadian and seasonal variations, and also during skeletal growth. 
Pre-clinical and translational studies using BTMs with sheep and goats as animal models in orthopaedic 
research studies to help in the evaluation of the fracture healing process and osteoporosis research are 
also described in this review. The available information from the reviewed studies was systematically 
organized in order to highlight the most promising BTMs in small ruminant research, as well as provide 
a wide view of the use of sheep and goat as animal models in orthopaedic research, type of markers and 
commercial assay kits with cross-reactivity in sheep and goat, method of sample and storage of serum and 
urine for bone turnover markers determination and the usefulness and limitations of bone turnover markers 
in the different studies, therefore an effective tool for researchers that seek answers to different questions 
while using BTMs in small ruminants.
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INTRODUCTION
In the last decades, small ruminants - sheep and 
goats - have been widely accepted as animal mod-
els in orthopaedic research (O’Loughlin et al. 2008, 
Reichert et al. 2009) especially due to their low 
cost, availability, acceptance as an experimental 
model, facility of handling and housing (Turner 
2007a), compliance, and docility (Newman et al. 
1995).
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The suitability of small ruminants as animal 
models for orthopaedic research results mainly 
from having the most similar body weight and 
long bones with dimensions compatible with 
application of implants and prostheses developed 
for humans (Newman et al. 1995, Anderson et al. 
1999, van der Donk et al. 2001). In this manner, 
compared with other species used in orthopaedic 
research, sheep and goats have an adequate body 
weight and long bones, with a macrostructure more 
similar to humans (Newman et al. 1995), despite 
the bone microstructure of small ruminants being 
less similar to humans than other animal models 
such as dogs (Pearce et al. 2007). Sheep have a 
predominance of plexiform bone until 3 to 4 years 
of age (Newman et al. 1995) due to fast growth in 
weight and size (Reinwald and Burr 2011) and just 
a predominance of secondary Haversian systems 
after 7 to 9 years of age with the presence of bone 
remodelling (Newman et al. 1995). Sheep also 
presents a trabecular bone density, mineralization 
and subsequently elevated strength relative to 
humans, that are variable according to skeletal 
location (Nafei et al. 2000, Liebschner 2004), 
nevertheless the bone mineral composition being 
apparently similar between small ruminants and 
humans (Ravaglioli et al. 1996).
Despite these macro- and micro-structural 
differences in bone tissue, studies with small 
ruminants used as animal models in orthopaedic 
research have increased considerably (Pearce et 
al. 2007), and more recently they have also been 
used for studying bone turnover markers (BTMs) 
(Sousa et al. 2014a). The BTMs are proteins which 
indicate bone metabolism (Sousa et al. 2014b), 
and are generally divided into collagenous bone 
formation markers, bone resorption markers and 
osteoclast regulatory protein markers (Leeming 
et al. 2006). Analysis of BTMs might supply 
information in a fast, effective, sensitive, specific, 
and low cost manner (Allen 2003). Nowadays, it is 
used in human medicine to help evaluate fracture 
risk, delayed fracture healing and consolidation 
process, and development of metabolic bone 
diseases (Vasikaran et al. 2011).
These similarities in biochemistry, biomechan-
ics, and bone histology make BTMs a resource in 
sheep and goats for pre-clinical and/or translational 
orthopaedic research studies and veterinary and 
animal science studies (Turner 2007b). Neverthe-
less, the reported biological variability of BTMs 
among age, gender, disease, recent fractures, ex-
ercise, time (Seibel 2005), diet (Nicodemo et al. 
1999, Liesegang and Risteli 2005, Liesegang et al. 
2013), seasonal changes (Arens et al. 2007) and 
circadian variation (Liesegang et al. 2003), which 
can contribute substantially to the variability of 
these parameters (Smith et al. 2011), are their main 
limitation (Cremers et al. 2008).
Therefore, the aim of this review was to collect 
the studies published in scientific literature until 
the present date concerning the use of BTMs in 
small ruminant research or to investigate the clini-
cal effectiveness of BTMs in pre-clinical or transla-
tional experimental orthopaedic research related to 
human medicine when sheep and goat are used as 
experimental animal models for this latter purpose.
BONE TURNOVER MARKERS
Bone tissue undergoes turnover along the animal 
lifespan (Seibel 2006) and that process is divided 
into two parts: modelling and remodelling (Clarke 
2008).
Modelling is a longitudinal and circumferential 
growth process due to mechanical and/or 
physiological influences (Clarke 2008), with 
longitudinal growth located at the epiphyseal 
plates until their fusion uniting the epiphysis and 
metaphysis through endochondral ossification 
(Altman et al. 2015). It also allows the adaptation 
of bone tissue, removing damage and maintaining 
its strength (Seeman 2009), and requires that 
the process of bone formation and resorption 
are independent from one another regarding 
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time and location (Raggatt and Partridge 2010). 
Remodelling is a process of bone replacement 
where bone formation outpaces bone resorption 
(Altman et al. 2015), to maintain bone strength and 
mineral homeostasis, regulated by osteoclasts and 
osteoblasts that sequentially carry out resorption of 
old bone and formation of new bone, keeping the 
new bone healthy (Clarke 2008). Bone remodelling 
predominates when bone is reaching maturity 
(Iglesias et al. 2011), but it does not influence the 
size and shape, although the internal architecture 
may have slight changes caused by external 
forces (Hadjidakis and Androulakis 2006). Bone 
formation and resorption are present in same site, 
but not at the same time in order to maintain bone 
mass (Raggatt and Partridge 2010).
The proteins produced during bone turnover 
are detectable mainly in serum in bone formation 
markers, whereas many of the bone resorption 
markers are detectable in both serum and urine 
(Allen 2003), and there are a significant number of 
commercial kits developed for use in humans that 
have cross-reactivity with other species, including 
sheep and goats (Tables I to III).
TABLE I 
Bone formation markers, method of analysis and available commercial assay kits.
Marker Tissue of origin Sample Method of analysis Available commercial Assay kit
Cross-Reactivity 
Sheep / Goat
BALP Bone Serum Colorimetric No commercial kit available NO / NO
Electrophoretic No commercial kit available NO / NO
Precipitation No commercial kit available NO / NO
CLA LIAISON BAP Ostase, Stillwater, MN, USA ? / ?
ELISA MicroVue BAP, Quidel Corporation, San Diego, CA, USA YES / YES
RIA Tandem-R-Ostase, Beckman Coulter, Brea, CA, USA YES / ?
OC Bone Serum CLA LIAISON Osteocalcin, Stillwater, MN, USA ? / ?
RIA BTI Human Osteocalcin RIA, Biomedical Technologies Inc, Stoughton, MA, USA ? / ?
ELISA MicroVue Osteocalcin, Quidel Corporation, 
San Diego, CA, USA YES / YES
BTI Intact Osteocalcin, Biomedical 
Technologies Inc, Stoughton, MA, USA ? / ?
Osteocalcin, SIGMA, Saint Louis, Missouri, 
USA ? / ?
Osteocalcin, GenWay Biotech, San Diego, 
CA, USA NO / NO
PINP Bone, soft tissue Serum CLA PINP Roche Diagnostics, Penzberg, Germany ? / ?
RIA UniQ Intact PINP, Orion Corporation, Espoo, Finland ? / ?
Serum or urine ELISA PINP, Neobiolab Inc, Cambridge MA, UK YES / YES
PICP Bone, soft tissue Serum RIA PICP, Orion Corporation, Espoo, Finland ? / ?
PICP DiaSorin, Stillwater, MN, USA YES / ?
ELISA MicroVue CICP, Quidel Corporation, San Diego, CA, USA YES / ?
Serum or urine PICP, Neobiolab Inc, Cambridge MA, UK YES / YES
BALP: Bone specific alkaline phosphatase; OC: Osteocalcin; PINP: Amino-terminal procollagen propeptides of collagen type 
I; PICP: Carboxy-terminal procollagen propeptides of collagen type I; RIA: Radioimmunoassay; ELISA: Enzyme-linked 
immunosorbant assay; CLA: Chemiluminescence immunoassay; YES: presence of cross-reactivity; NO: absence of cross-
reactivity; ?: no data available.
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TABLE II 
Bone resorption markers, method of analysis and available commercial assay kits.
Marker Tissue of origin Sample
Method of 
analysis Available commercial Assay kit
Cross-Reactivity 
Sheep / Goat
HYP Bone, soft 
tissue, cartilage
Serum or urine ELISA HYP, Neobiolab Inc, Cambridge MA, UK YES / YES
Urine Colorimetric 
HPLC
No commercial kit available NO / NO
DPD Bone, dentin Urine ELISA MicroVue DPD, Quidel Corporation, San 
Diego, CA, USA
YES / ?
HLPC No commercial kit available NO / NO
Serum or urine ELISA MicroVue tDPD, Quidel Corporation, San 
Diego, CA, USA
YES / ?
DPD, Neobiolab Inc, Cambridge MA, UK YES / YES
PYD Bone, cartilage, 
blood vessels
Urine HPLC No commercial kit available NO / NO
ELISA MicroVue Serum PYD, Quidel Corporation, 
San Diego, CA, USA
YES / ?
RIA No commercial kit available NO / NO
Serum or urine ELISA PYD, Neobiolab Inc, Cambridge MA, UK YES / YES
ICTP Bone, skin Serum Colorimetric No commercial kit available NO / NO
RIA ICTP, Incstar Corporation, Stillwatter, MN, 
USA
? / ?
UniQ ICTP, Orion Corporation, Espoo, 
Finland
? / ?
ICTP DiaSorin, Stillwatter, MN, USA NO / NO
ELISA UniQ ICTP EIA, Orion Corporation, Espoo, 
Finland
? / ?
Serum or urine ICTP, Neobiolab Inc, Cambridge MA, UK YES / YES
CTx Bone Serum CLA β-Crosslaps Roche Diagnostics Penzberg, 
Germany
? / ?
RIA No commercial kit available NO / NO
ELISA Serum CrossLaps, Biointernational, Yvette, 
France
YES / ?
Urine CLA β-CrossLaps Roche Diagnostics Penzberg, 
Germany
? / ?
RIA CrossLaps RIA, Osteometer Biotech, Herlev, 
Denmark
? / ?
ELISA CrossLaps, Osteometer Biotech, Herlev, 
Denmark
YES / YES
Serum or urine ELISA CTx, Neobiolab Inc, Cambridge MA, UK YES / YES
NTx Bone Serum RIA No commercial kit available NO / NO
ELISA Osteomark Ostex International Inc., Seattle, 
WA, USA
YES / ?
 NTx MyBioSourse, San Diego, CA, USA
Urine RIA No commercial kit available NO / NO
Serum or urine ELISA NTx, Neobiolab Inc, Cambridge MA, UK ? / YES
Cathepsin k Bone Serum ELISA Cathepsin k ELISA Kit, Antibodies-online, 
Atlanta, Georgia, USA
? / ?
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During the process of bone formation by osteo-
blasts, formation markers are represented by serum 
total (ALP) and the bone-specific isoform of alka-
line phosphatase (BALP), serum osteocalcin (OC) 
and two molecules which are released during the 
type I collagen molecule synthesis – serum procol-
lagen type I carboxy- and amino-terminal propep-
tides (PICP and PINP, respectively) (Seibel 2002). 
In the bone resorption process there is a breakdown 
of type I collagen, so resorption markers are rep-
resented by serum C-terminal telopeptide of type 
I collagen (serum ICTP), urinary collagen type I 
cross-linked C- and N-telopeptide (CTx and NTx), 
urinary hydroxyproline (HYP), total and free uri-
nary pyridinoline and deoxypyridinoline (PYD 
and DPD) and also by serum tartrate-resistant acid 
phosphatase (TRAP) as an enzyme produced by 
osteoclasts during their bone resorption activity 
(Seibel 2002) (Figure 1).
BONE FORMATION MARKERS
ALKALINE PHOSPHATASE
Alkaline phosphatase (ALP) is a glycoprotein that 
is connected to the extracellular surface of cells 
and is synthesized in a variety of tissues, such as 
intestines, placenta, and germ cells (Millan 2006). 
Animals have four isoforms of ALP – bone-specific 
Marker Tissue of origin Sample
Method of 
analysis Available commercial Assay kit
Cross-Reactivity 
Sheep / Goat
TRAP Bone Serum RIA No commercial kit available NO / NO
ELISA MicroVue TRAP 5b, Quidel Corporation, San 
Diego, CA, USA
YES / YES
Osteolink-TRAP b, Nitto Boseki Corporation, 
Tokio, Japan
? / ?
Bone TRAP SBA, Science, Boldon, UK ? / ?
Serum or urine TRAP, Neobiolab Inc, Cambridge MA, UK YES / YES
HYP: Hydroxyproline; DPD: Deoxypyridinoline; PYD: Pyridinoline; ICTP: Carboxy-terminal telopeptide of type I collagen; CTx: 
cross-linked C-terminal telopeptides of type I collagen; NTx: cross- linked N-terminal telopeptides of type I collagen; TRAP 5b: 
Tartrate-resistant acid phosphatase isoenzyme 5b; RIA: Radioimmunoassay; ELISA: Enzyme-linked immunosorbant assay; CLA: 
Chemiluminescence immunoassay; HPLC: High-performance liquid chromatography.
TABLE II (continuation)
TABLE III 
Osteoclast regulatory proteins, method of analysis and available commercial assay kits.
Marker Tissue of origin Sample
Method of 
analysis Available commercial Assay kit
Cross-Reactivity 
Sheep / Goat
RANKL Bone, 
blood
Serum ELISA
 
Human Serum RANKL Free ELISA Kit, Biomedica 
Medizinprodukte, GmbH & Co. KG, Wien, Austria
? /?
RANKL, Immundiagnostik AG, Bensheim, Germany ? /?
Serum or urine RANKL, Neobiolab Inc, Cambridge MA, UK YES / YES
RANK Bone Serum ELISA RANK R&D Systems, Minneapolis, MN, USA ? / ?
OPG Bone Serum ELISA Human Osteoprotegerin ELISA kit, BioVendo 
Laboratory Medicine, Inc., Labogen, Czech Republic
NO / NO
Osteoprotegerin, Immundiagnostik AG, Bensheim, 
Germany
? / ?
Osteoprotegerin R&D Systems, Minneapolis, MN, 
USA
? / ?
  Serum or urine  OPG, Neobiolab Inc, Cambridge MA, UK YES / YES
RANKL: receptor activator of nuclear factor NF-κB ligand; RANK: receptor activator of nuclear factor NF-κB; OPG: 
osteoprotegerin; ELISA: Enzyme-linked immunosorbant assay.
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ALP (BALP), intestinal ALP, liver ALP, and in 
dogs also the corticosteroid-induced ALP. This 
variation would render difficult the interpretation 
of possible variations of the ALP isoenzymes 
(Allen 2003). Bone ALP has been used due to its 
high sensitivity as bone formation marker (Seibel 
2006). It is produced by osteoblasts (Millan 
2006) and is involved in the calcification of bone 
↓
↓
↓
↓
κ
Figure 1 – Flow diagram of BTMs produced during the bone turnover process.
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matrix (Masrour and Mahjoub 2012) through the 
hydrolysis of phosphate esters on the osteoblast cell 
surface, resulting in a high extracellular inorganic 
phosphate concentration (Whyte 1994).
OSTEOCALCIN
Osteocalcin (OC) is synthesized by mature osteo-
blasts, odontoblasts, and hypertrophic chondro-
cytes and it is vitamin K dependent protein. It has 
three residues of the calcium-binding amino acid, γ 
- carboxyglutamic acid (Gla). Its function is poorly 
understood, although it is primarily deposited in 
the bone extracellular matrix (ECM), with a small 
amount present in the blood stream (Cremers et 
al. 2008). Serum OC is a marker of osteoblastic 
activity and its serum level thus reflects the rate of 
bone formation (Seebeck et al. 2005), influences 
bone mineralization by binding calcium and conse-
quently hydroxyapatite (Neve et al. 2013).
PRO-COLLAGEN TYPE I PROPEPTIDES
Collagen type I is produced by osteoblasts in the 
last stage of new bone formation (Allen 2003). 
The procollagen undergoes enzymatic cleavage 
producing the C- and N-terminal procollagen type 
I extension peptides (PICP and PINP, respectively), 
both extension are cleared by the liver and may be 
added to the bone ECM (Watts 1999). Nevertheless, 
type I collagen does not depend exclusively on the 
bone tissue turnover because it is also a component 
of other soft tissues as fibro-cartilage, tendon, 
skin, gum, intestine, heart valve, large vessels, 
and muscle. However, as the metabolism of type 
I collagen is faster in the bone tissue than in other 
tissues, changes in type I collagen are considered 
representative of bone collagen synthesis (Cremers 
et al. 2008). It is suggested that PINP is useful 
in early detection of non union processes with 
potential for study of the fracture healing process 
(Coulibaly et al. 2010), although in humans it is 
unknown whether there exists a correspondence 
between PINP and the progression of fracture 
healing (Moghaddam et al. 2011).
BONE RESORPTION MARKERS
DEOXYPYRIDINOLINE AND PYRIDINOLINE
The collagen fibrils recently deposited in bone 
ECM are stabilized by intra- and intermolecular 
cross links helping to build the mature collagen 
molecule (Cepelak and Cvorišcec 2009).
The pyridinium cross links – deoxypyridinoline 
(DPD) and pyridinoline (PYD) are formed during 
extracellular maturation of fibrillar collagens 
(Gerrits et al. 1995). The PYD is found in bone 
and cartilage tissues and ligaments (Watts 1999) 
while DPD is found in bone and dentin (Delmas et 
al. 2000), so in the bloodstream PYD is generally 
more abundant (Cremers et al. 2008), although DPD 
is more specific as a resorption marker for bone 
tissue (Seibel et al. 1992). In a study with sheep 
after ovariectomy, this animal model demonstrated 
relevance as a model for osteoporosis due to the 
values of PYD and OC found (Newton et al. 2004). 
CARBOXY-TERMINAL TELOPEPTIDE OF 
COLLAGEN TYPE I AND AMINO-TERMINAL 
TELOPEPTIDE OF COLLAGEN TYPE I
The N-terminal (NTx) and C-terminal telopeptide 
of collagen type I (CTx) are fragments of the type 
I collagen molecule composed by a short peptide 
sequence from the non-helical domain of this 
molecule (Chubb 2012), attached by a pyridinium 
crosslink (Allen et al. 2000). Both markers are 
sensitive and reliable indicators of the bone 
resorption process (Cremers et al. 2008) and final 
products of the metabolism of bone ECM, amino 
acids, and free or peptide-bound PYD or DPD 
(Allen et al. 2000).
The CTx is not specific as a resorption marker 
for bone tissue since it is identified not only in 
bone, but also in skin, dentine, and tendon, and 
these peptide fragments could also be derived from 
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other types of collagen (Chubb 2012). However, 
CTx could be used for monitoring the bone healing 
process because it was detected that variations in 
its levels corresponded to bone resorption in an 
experimental fracture healing study performed in 
dogs where two different osteosynthesis techniques 
were used (Paskalev and Krastev 2010).
CARBOXY-TERMINAL TELOPEPTIDE OF TYPE I 
COLLAGEN - MATRIX METALLOPROTEINASE
Cleavage of the type I collagen molecule by the 
matrix metalloproteinases (MMP) results in the 
formation of cross-linked C-terminal telopeptide of 
type I collagen (CTX-MMP or ICTP) (Cremers et 
al. 2008), suitable to represent osteoclastic activity 
(Allen et al. 2000).
The ICTP is an indicator for mobilization of 
bone tissue around parturition and at the beginning 
of lactation in sheep and goats (Liesegang et al. 
2007). In dogs with osteosarcoma (Hintermeister 
et al. 2008) and horses during physical training, 
this marker has not revealed itself suitable for 
determining bone resorption since it did not show 
correlation with other resorption markers, however 
it was an indicator of the rate of bone turnover 
(Price et al. 1995).
TARTRATE-RESISTANT ACID PHOSPHATASE
Tartrate-resistant acid phosphatase (TRAP) is a 
bone resorption marker, but not originated from 
the degradation of type I collagen (Hannon et al. 
2004). It is a glycoprotein produced by osteoclasts, 
activated macrophages, and dendritic cells 
(Leeming et al. 2006). There is an isoenzyme 5, 
from a total of 6 isoenzymes of the acid phosphate 
identified by electrophoresis, which through 
protease cleavage presents two isoforms (a, b) – 
the TRAP 5a is sialylated and TRAP 5b is produced 
by osteoclasts, and the latter proposed to reflect 
osteoclast activity (Delmas et al. 2000, Leeming et 
al. 2006). The TRAP could be a suitable resorption 
marker for detection of normal or delayed fracture 
healing process in sheep (Seebeck et al. 2005) or 
dogs (Sousa et al. 2011).
CATHEPSIN K
Cathepsin K is part of the cysteine protease family 
and has the ability to cleave both helical and 
telopeptide regions of collagen type I (Leeming et al. 
2006). This enzymatic cleavage is able to degrade, 
at low pH, several proteins of the bone ECM, 
namely the telopeptide and helical regions of the 
collagen type I molecule, the OC and osteopontin 
(Cremers et al. 2008). This marker could be used as 
a tool to measure bone resorption, such as in canine 
osteosarcoma clinical cases (Schmit et al. 2012).
VARIABILITY OF BONE TURNOVER MARKERS
The BTMs could suffer constant variation through-
out the lifetime of an individual (Sousa et al. 
2014b). However, variation between individuals is 
also a great cause of oscillation in markers, specifi-
cally due to biological variability, together with the 
analytical variability introduced by the different as-
say techniques (Vasikaran et al. 2011).
Biological variability can be influenced by 
many uncontrollable factors (Cremers et al. 2008), 
such as growth (Sousa et al. 2014a), geographical 
location (Liesegang et al. 2013), pregnancy and 
lactation (Liesegang et al. 2006, Liesegang et 
al. 2007), and controllable factors, such as diet 
(MacLeay et al. 2004a, b, Liesegang et al. 2013), 
and season of the year (Arens et al. 2007), which 
can be mitigated in clinical studies (Liesegang 
2008). In short, biological variability is affected 
by any factor that influences the bone remodelling 
(Watts 1999).
Analytical variability has been minimized due 
to automated platform technology, however, there 
could be variations in results between different 
methods (Cremers et al. 2008) and the development 
of new analytical techniques requires previous 
validation (Seibel et al. 2001).
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The high inter-individual variability of BTMs 
is their main limitation for clinical use due to the 
difficulty to establish reference ranges for serum 
and urinary BTM levels (Souberbielle et al. 1999), 
although bone markers are an effective tool in 
clinical studies due to reliable, fast, non-invasive, 
and cost effective assays with improved sensitivity 
and specificity (Wheater et al. 2013).
SAMPLE AND STORAGE
Blood collection for measuring BTMs must be done 
at a specific time (morning) to avoid the influence 
of circadian variations (Klein et al. 2004, Seebeck 
et al. 2005, Dias et al. 2008, Sousa et al. 2014a, b). 
Blood samples can be collected from the cephalic 
vein (Klein et al. 2004) or jugular vein (Dias et al. 
2008, Sousa et al. 2014a, b) into serological tubes 
containing no anticoagulant (Vernon et al. 2010), 
and centrifuged (3000 rpm for 10 min) within 30 
min of collection (Liesegang et al. 2007). Urine 
can be obtained using a special external urine 
collector (Windhagen et al. 2002) or collected by 
cystocentesis (Allen et al. 2000). Urine and serum 
samples should be stored at -20°C for mineral 
analyses (Chanetsa et al. 2000, Taylor et al. 2009, 
Sousa et al. 2014a) and at -80°C until determination 
of BTMs (Seebeck et al. 2005, Tatara 2008, Sousa 
et al. 2014b), which provides molecular stability 
for several months (Lomeo and Bolner 2000).
ANIMAL AND VETERINARY SCIENCE STUDIES
Characteristics of the animal and veterinary science 
studies regarding population, type of studies, 
time, and conclusion (Table SIV – Supplementary 
Material).
DIET
According to Liesegang and Risteli (2005) 
Liesegang et al. (2013), MacLeay et al. (2004a, b) 
and Nicodemo et al. (1999) nutritional studies using 
BTMs were influenced by different diets, though 
this influence was not statistically significant. 
MacLeay et al. (2004a) concluded that during the 
administration of a diet that induced metabolic 
acidosis in mature ewes, there were no significant 
changes in serum BALP and DPD levels. In another 
study by Liesegang et al. (2013) with sheep grazing 
at different altitudes, it was not possible to confirm 
the interference of diet in the serum variation 
of ICTP or BALP, but high bone turnover was 
confirmed. Also, in a study by Liesegang and Risteli 
(2005) where a diet with varying calcium content 
was used, it was not possible to demonstrate the 
influence of the diet on bone mineral metabolism 
in growing goats and sheep, possibly due to the 
short duration of this study, where only the sheep 
showed a variation in BMD due to an increase in 
calcium intake. However, Wilkens et al. (2010) 
demonstrated that sheep were a suitable model for 
studies with varying diets, calcium deficiency, and 
calcitrol.
EXERCISE
Liesegang and Risteli (2005) demonstrated that 
sheep in pasture at high altitudes had an increase 
in bone turnover and bone mineral content without 
clear cause, one possible factor being the increase 
in exercise. In another study in lambs, Vernon et al. 
(2010) concluded that the markers used were not 
adequate to indicate the effects of forced exercise.
GESTATION AND LACTATION
Liesegang et al. (2006) noticed that the interval 
between parturition and early lactation in sheep and 
goats required a high nutritional value of calcium 
due to losses to the fetus and lactation, occurring 
inefficiency of calcium absorption, leading to 
increases in bone remodelling to help replace 
maternal bone loss classified as a physiological 
mechanism. During a second pregnancy, bone 
loss was less significant compared with the first 
pregnancy and the lactation greater, possibly due 
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to the adaptation of the organism (Liesegang et al. 
2007). Finally, it was concluded that sheep were 
more adapted to the loss of calcium in comparison 
to goats, that had a lower bone mineral density and 
bone mineral content before parturition (Liesegang 
and Risteli 2005) increased bone turnover, resulting 
in a higher activity of bone metabolism and 
sensitivity to changes in calcium during pregnancy 
and lactation (Liesegang et al. 2003).
CIRCADIAN AND SEASONAL VARIATION
Chavassieux et al. (1991) reported that bone 
remodelling was influenced by the photoperiod, 
with decrease in bone remodelling occurring 
between spring and summer. Arens et al. (2007) 
confirmed that bone mass increases in summer and 
decreases in winter, so taking seasonal variation 
into account is fundamental in studies using BTMs. 
Liesegang et al. (2003) reported an increase in the 
rate of bone formation during the evening and night, 
indicating the influence of the circadian rhythm in 
bone turnover. Sousa et al. (2014b) concluded that 
the short-term variability should be considered 
during interpretation of data, such as circadian and 
seasonal variations, nevertheless the short-term 
biological variability do not represent a limitation 
for the use of BTMs.
SKELETAL GROWING
Pastoureau et al. (1991) mention that sheep are a 
good model to study the bone growth in growing 
lamb. It was reported that goats showed a more 
accelerated bone remodelling that sheep, which 
was demonstrated by ICTP, CTx (Liesegang et al. 
2003), BALP (Liesegang et al. 2003, Sousa et al. 
2014a), and OC determinations in various studies 
(Pastoureau et al. 1991, Liesegang et al. 2003). 
Collignon et al. (1996) demonstrated that bone 
growth since the fetal stage produces alterations in 
serum OC and BALP, confirming the usefulness of 
these markers in bone formation and growth. Scott 
et al. (1997) reported that OC, BALP, DPD, and 
PYD may be useful for detection of changes in bone 
growth caused by deficient diets, and Wan Zahari 
et al. (1994) reported that high phosphorus diets 
resulted in increased bone resorption (increased 
TRAP) in lambs. However, Chanetsa et al. (2000) 
exposed castrated lambs to an oestrogen agonist. In 
this study, bone growth was observed, but no effect 
on markers of bone remodelling was noticed.
PRE-CLINICAL AND TRANSLATIONAL 
ORTHOPAEDIC RESEARCH STUDIES
The characteristics of the pre-clinical and transla-
tional orthopaedic research studies, such as popula-
tion, type of studies, time, and conclusion are listed 
in Table SIV.
FRACTURE HEALING PROCESS
Tralman et al. (2013) and Windhagen et al. (2002) 
reported that the serum markers of bone formation 
are useful for reflecting the bone healing process, 
and Goebel et al. (2009) suggested that FGF23 
is a good marker to indicate the healing process. 
Seebeck et al. (2005) stated that degradation of soft 
callus can be determined by serum PIIINP during 
the bone fracture healing process and Schmidt et 
al. (2008) concluded that it is possible to monitor 
the maturation of bone callus with the total ALP 
and NTx. However, without individual reference 
values, BTMs become a weak tool to determine the 
prognosis of bone consolidation (Klein et al. 2004).
OSTEOPOROSIS
Newton et al. (2004) reported that ovariectomized 
(OVX) ewe were a useful model due to alterations 
in trabecular bone architecture along with the 
decrease in oestrogen levels, which resemble 
women in early menopause and Turner (2001) 
suggested that old OVX ewes could be a valid 
model for bone loss due to oestrogen deficiency. 
Johnson et al. (2002) reported that 6 months after 
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OVX in sheep there was a decrease in alveolar 
bone BMD which became serious during the next 
6 months. However, Sigrist et al. (2007) reported 
that in sheep, 6 months after the OVX, the markers 
for formation and resorption returned to baseline, 
indicating that the model was not appropriate for 
human postmenopausal osteoporosis. Kreipke et 
al. (2014) reported that OVX induces the necessary 
changes in bone microarchitecture for studying 
osteoporosis, but after a year, the changes in 
architecture stabilize in ovine. Chavassieux et al. 
(2001) reported that in goats, remodelling occurred 
only in the cortical bone tissue regions, which was 
also demonstrated by increased levels of CTx one 
month after OVX and OC three months after OVX.
Ding et al. (2010) and Andreasen et al. (2015) 
stated that the induction by glucocorticoids in 
sheep is similar to the change in the microstructure 
of human bone also induced by long-term 
glucocorticoid treatment, therefore being a useful 
model. MacLeay et al. (2004b) though not knowing 
what the true mechanism is involved in diets that 
induce metabolic acidosis in bone loss, concluded 
that the sheep model is useful for studies of 
osteoporosis induced by diet.
Therefore, small ruminant models are important 
for the study of human osteoporosis (Chavassieux 
et al. 1997, Lill et al. 2002a, b, Andreasen et al. 
2015, Kielbowicz et al. 2015, 2016) induced by 
OVX and with attention to continuous treatment 
with glucocorticoids to maintain the osteoporotic 
bone condition (Ding et al. 2010).
CONCLUSIONS
The suitability of the determination of BTMs in 
small ruminants is already confirmed in numerous 
animal and veterinary sciences studies and also 
in preclinical and/or translational studies in 
orthopaedic research, in addition to imaging, 
mechanical, histological and histomorphometric 
analyses. Their advantage relies on a fast and 
non-invasive assessment via biochemical analysis 
of serum or urine samples, although the referred 
negative aspect of using BTMs in the clinical setting 
is related with their high biological variability. 
Particularly in sheep, BTMs have been used to 
estimate the extent of the osteogenic response at a 
local level at the fracture healing site, as precocious 
indicators of possible bone healing disturbances. 
BTMs could provide important information 
concerning bone metabolism at a systemic level, 
namely about bone remodelling process during 
induction of osteoporosis and its treatment in 
experimental orthopaedic studies. Recently it was 
developed a study by Baharuddin et al. (2014) 
in sheep with osteoclast regulatory protein – 
receptor activator of nuclear factor NF-κB ligand 
(RANKL) produced by osteocytes, osteoblasts 
and immune system cells, its membrane-bound 
receptor (RANK) in the osteoclast precursor cells 
and osteoprotegerin (OPG) as new potential bone 
markers in future (Sousa et al. 2015), nevertheless 
more studies would be necessary to assess the 
usefulness of BTMs in this scientific field.
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